Securing wider EU commitment to the elimination of hepatitis C virus

In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030. Since then, many European countries have made progress towards HCV elimination. Multiple programmes—from the municipality level to the EU level—were launched, resulting in an overall decrease in viremic HCV infections and liver‐related mortality. However, as of 2021, most countries are not on track to reach the 2030 HCV elimination targets set by the WHO. Moreover, the COVID‐19 pandemic has resulted in a decrease in HCV diagnoses and fewer direct‐acting antiviral treatment initiations in 2020. Diagnostic and therapeutic tools to easily diagnose and treat chronic HCV infection are now well established. Treating all patients with chronic HCV infection is more cost‐saving than treating and caring for patients with liver‐related complications, decompensated cirrhosis or hepatocellular carcinoma. It is more important than ever to reinforce and scale‐up action towards HCV elimination. Yet, efforts urgently need the dedicated commitment of policymakers at all governmental and policy levels. Therefore, the third EU Policy Summit, held in March 2021, featured EU parliamentarians and other key decision makers to promote dialogue and take strides towards securing wider EU commitment to advance and achieve HCV elimination by 2030. We have summarized the key action points and reported the ‘Call‐to‐Action’ statement supported by all the major relevant European associations in the field.

[1]  M. Persico,et al.  Hepatitis C screening during SARS‐CoV‐2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[2]  F. Tacke,et al.  Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany , 2022, Journal of viral hepatitis.

[3]  P. Lampertico,et al.  Implementation of HCV screening in the 1969–1989 birth‐cohort undergoing COVID‐19 vaccination , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[4]  Jisoo A. Kwon,et al.  Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. , 2022, The lancet. Gastroenterology & hepatology.

[5]  B. Maasoumy,et al.  Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin als Reserveregime nach Sofosbuvir + Velpatasvir + Voxilaprevir Re-Therapieversagen , 2021, Zeitschrift für Gastroenterologie.

[6]  J. Lazarus,et al.  Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[7]  P. Hayes,et al.  Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs , 2021, Journal of hepatology.

[8]  F. Ponziani,et al.  Management of liver disease in Italy after one year of the SARS‐CoV‐2 pandemic: A web‐based survey , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[9]  V. Frochot,et al.  Intravenous ketamine is a risk factor for jaundice in Covid-19 patients , 2021, Journal of Hepatology.

[10]  H. Wedemeyer,et al.  Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience , 2021, Open forum infectious diseases.

[11]  M. Andreoni,et al.  Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  M. Persico,et al.  Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: the “Casola di Napoli” cohort study , 2021, Digestive and Liver Disease.

[13]  A. Alberti,et al.  Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. , 2021, Epidemics.

[14]  Michael V. D’Ambrosio,et al.  Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy , 2020, Cell.

[15]  S. Hutchinson,et al.  Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data , 2021 .

[16]  D. Hüppe,et al.  Versorgungsprobleme von Patienten mit chronischer Hepatitis C während der COVID-19-Pandemie und der Lockdown-Verordnungen , 2020, Zeitschrift für Gastroenterologie.

[17]  D. Raben,et al.  Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  J. A. Cook,et al.  Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study , 2020, Journal of Hepatology.

[19]  R. Malekzadeh,et al.  The case for simplifying and using absolute targets for viral hepatitis elimination goals , 2020, Journal of viral hepatitis.

[20]  J. Pawlotsky,et al.  EASL recommendations on treatment of hepatitis C - Final update of the series. , 2020, Journal of hepatology.

[21]  J. Pawlotsky,et al.  Impact of COVID-19 on global HCV elimination efforts , 2020, Journal of Hepatology.

[22]  C. James,et al.  The impact of COVID-19 on hepatitis elimination , 2020, The Lancet Gastroenterology & Hepatology.

[23]  J. Lazarus,et al.  Global hepatitis C elimination: an investment framework. , 2020, The lancet. Gastroenterology & hepatology.

[24]  J. Lazarus,et al.  Progress towards elimination goals for viral hepatitis , 2020, Nature Reviews Gastroenterology & Hepatology.

[25]  E. Buscarini,et al.  High rates of 30-day mortality in patients with cirrhosis and COVID-19 , 2020, Journal of Hepatology.

[26]  Stephen R. Spriggs,et al.  CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020 , 2020, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[27]  I. Waked,et al.  Screening and Treatment Program to Eliminate Hepatitis C in Egypt. , 2020, The New England journal of medicine.

[28]  A. Gori,et al.  Coronavirus disease 2019 and transplantation: A view from the inside , 2020, American Journal of Transplantation.

[29]  H. Razavi,et al.  Optimization of hepatitis C virus screening strategies by birth cohort in Italy , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[30]  G. Dore,et al.  Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. , 2020, Journal of hepatology.

[31]  H. Razavi,et al.  Global timing of hepatitis C virus elimination in high‐income countries , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[32]  G. Papandreou,et al.  Securing sustainable funding for viral hepatitis elimination plans , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[33]  N. Luhmann,et al.  We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade , 2019, Journal of internal medicine.

[34]  S. Marx,et al.  964 Patient Flow Across Physician Specialties Over the Course of the Hepatitis C Care Cascade: A Real World Analysis From the United States , 2019, American Journal of Gastroenterology.

[35]  Rachel Glass,et al.  Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol) , 2019, BMJ Open.

[36]  M. Buti,et al.  Too many people with viral hepatitis are diagnosed late — with dire consequences , 2019, Nature Reviews Gastroenterology & Hepatology.

[37]  J. Lazarus,et al.  The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  E. Bjornsson,et al.  THU-412-Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection: Results from the treatment as prevention for hepatitis C (Trap HepC) program , 2019, Journal of Hepatology.

[39]  J. Ward,et al.  Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct‐Acting, Pangenotypic Treatment Regimens , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  R. Peeling,et al.  Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. , 2019, The lancet. Gastroenterology & hepatology.

[41]  Y. Yazdanpanah,et al.  Assessing the cost-effectiveness of hepatitis C screening strategies in France. , 2018, Journal of hepatology.

[42]  K. Pottie,et al.  The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review , 2018, International journal of environmental research and public health.

[43]  A. Hatzakis,et al.  HCV elimination among people who inject drugs. Modelling pre- and post–WHO elimination era , 2018, PloS one.

[44]  J. Lazarus,et al.  The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations , 2018, Seminars in Liver Disease.

[45]  M. Pitt,et al.  HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients , 2018 .

[46]  J. Lazarus,et al.  Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe , 2018, Journal of viral hepatitis.

[47]  M. Jauffret-Roustide,et al.  Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. , 2018, Journal of hepatology.

[48]  H. Vroling,et al.  Public health guidance on prevention and control of blood-borne viruses in prison settings , 2018 .

[49]  J. Grebely,et al.  Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis , 2017, Expert review of molecular diagnostics.

[50]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[51]  J. Lazarus,et al.  Micro-elimination - A path to global elimination of hepatitis C. , 2017, Journal of hepatology.

[52]  M. Buti,et al.  Late presentation of chronic viral hepatitis for medical care: a consensus definition , 2017, BMC Medicine.

[53]  B. Ringe,et al.  Niedrige Seroprävalenz von Hepatitis C bei Flüchtlingen in Deutschland im Jahr 2015 , 2017, Notfall + Rettungsmedizin.

[54]  S. Gilbody,et al.  Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis , 2016, The lancet. Psychiatry.

[55]  D. Hedrich Drug-related infectious diseases in Europe , 2015 .

[56]  M. Buti,et al.  Historical epidemiology of hepatitis C virus (HCV) in selected countries , 2014, Journal of viral hepatitis.

[57]  M. Hellard,et al.  Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. , 2014, International journal of epidemiology.

[58]  R. Evans European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[59]  S. Holmberg,et al.  Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010. , 2013, American journal of public health.

[60]  A basis for health policy on aging. Report from the World Health Organization Regional Office for Europe. , 1982, Community medicine.

[61]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .